Respiratory News and Research

RSS

EarlySense's new WiFi patient monitoring system receives FDA clearance and CE approval

EarlySense, which is currently bringing to market the most advanced, contact-free, patient monitoring solution for hospitals and nursing homes, announced today that it has received FDA clearance and CE approval for the new wireless (WiFi) communications component of its solution.

13 Jun 2011

STCEID to establish Center of Excellence in Infection Genomics

The South Texas Center for Emerging Infectious Diseases at The University of Texas at San Antonio announced today it will receive $4.6 million over the next five years from the U.S. Department of Defense's Army Research Office to establish a Center of Excellence in Infection Genomics to support microbiology research, teaching and outreach activities aligned with Army priorities.

13 Jun 2011

Five guidelines for avoiding ventilators improve pediatric outcomes, reduce costs of care

Guidelines that reduce the use of mechanical ventilation with premature infants in favor of a gentler form of respiratory support can profoundly affect those children's outcomes while reducing the cost of care, according to a team of researchers at Children's Hospital Boston.

13 Jun 2011

HHS adds eight substances to 12th Report on Carcinogens

The U.S. Department of Health and Human Services added eight substances to its Report on Carcinogens, a science-based document that identifies chemicals and biological agents that may put people at increased risk for cancer.

13 Jun 2011

Noninvasive ventilation can shorten intubation time and may reduce risk of post-extubation ARF

Noninvasive ventilation (NIV) used as a weaning technique for mechanically ventilated patients can shorten intubation time and may reduce the risk of post-extubation acute respiratory failure (ARF), according to French researchers.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

Luminex Corporation and the Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene today announced that Luminex's newly released xTAG Gastrointestinal Pathogen Panel (GPP) is being used successfully as a first-line screen for patients at Kliniken der Stadt Koln suspected of having an E. coli infection.

From Luminex 10 Jun 2011

Quest Diagnostics receives MDEA gold award for Simplexa/3M technology

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa molecular diagnostic test on the 3M Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday in New York City.

From Quest Diagnostics 10 Jun 2011

Non-alcoholic wheat beer has positive effect on athletes' health

Many amateur athletes have long suspected what research scientists for the Department of Preventative and Rehabilitative Sports Medicine of the Technische Universitaet Muenchen at Klinikum rechts der Isar have now made official: Documented proof, gathered during the world's largest study of marathons, "Be-MaGIC", that the consumption of non-alcoholic weissbier, or wheat beer, has a positive effect on athletes' health.

10 Jun 2011

New bariatric bed

Twenty-percent of the adult U.S. population is obese, including approximately five percent that are considered morbidly obese. The direct health issues, related complications and safety challenges affecting this population are far reaching and well documented. VitalGo, Inc., a provider of advanced technology-based solutions for medical staff safety, patient safety and home care, has announced the immediate availability of the new bariatric version of its Total Lift Bed™ (TLB) which addresses a wide variety of care, treatment and safety issues for patients weighing up to 1,000 lbs.

9 Jun 2011

Respira introduces breakthrough Dry Powder Inhaler

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, introduces the company's Dry Powder Inhaler (DPI) as a breakthrough solution for the pharmaceutical industry. Based on proprietary drug engine technology (DET), Respira Therapeutics' DPI significantly improves therapeutic performance and enables addressing the unmet medical needs of patients with severe respiratory diseases.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Study determines surfactant protein-D as 'a good predictor' of cardiovascular disease

A blood protein known as surfactant protein-D (SP-D), which is mainly synthesised in the lungs, has been described as "a good predictor" of cardiovascular disease following a large study in North America.

8 Jun 2011

New research on spinal muscular atrophy

Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences, researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies."

8 Jun 2011

FDA grants orphan drug designation for Edison's EPI-743 to treat inherited mitochondrial diseases

Edison Pharmaceuticals, Inc. announced today the United States Food and Drug Administration has granted orphan drug designation to EPI-743 for treatment of inherited mitochondrial respiratory chain diseases.

8 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

Respiratory News and Research

EarlySense's new WiFi patient monitoring system receives FDA clearance and CE approval

STCEID to establish Center of Excellence in Infection Genomics

Five guidelines for avoiding ventilators improve pediatric outcomes, reduce costs of care

HHS adds eight substances to 12th Report on Carcinogens

Noninvasive ventilation can shorten intubation time and may reduce risk of post-extubation ARF

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

Quest Diagnostics receives MDEA gold award for Simplexa/3M technology

Non-alcoholic wheat beer has positive effect on athletes' health

New bariatric bed

Respira introduces breakthrough Dry Powder Inhaler

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Study determines surfactant protein-D as 'a good predictor' of cardiovascular disease

New research on spinal muscular atrophy

FDA grants orphan drug designation for Edison's EPI-743 to treat inherited mitochondrial diseases

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Survivors of childhood cancer at increased risk of developing subsequent primary neoplasms

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News